Latest Content

The FDA approved Viatris' Gwyn Lo, a once-weekly low-dose estrogen (20 mcg) contraceptive patch, based on phase 3 LUMINOUS data showing a Pearl Index of 4.14 pregnancies per 100 woman-years and strong adhesion (98.7% intact). It's approved for women with BMI under 30; common side effects included application-site irritation and intercycle bleeding. Available later in 2026.

Global third-dose hepatitis B (HepB3) vaccine coverage reached 81.8% in 2023, but persistent gaps in Africa and South Asia threaten WHO elimination goals.

The OVERLORD-MS trial finds rituximab matches ocrelizumab in relapsing multiple sclerosis, with similar MRI control, relapses, and safety.

Experts at the Washington, DC, Pop Health Roundtable discussed delays in ILD diagnosis, multidisciplinary care, antifibrotic therapy, and insurance barriers.

All from July, these 5 novel therapeutics each claimed a “first” in their category.

Constrained optimization empirically derived social risk weights that gave equal influence to subgroup performance by dual eligibility and disability in overall contract scores.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

This study links county-level social vulnerability to variation in Medicare Advantage prior authorization policies.

Accelerated approval is granted to RP1 plus nivolumab for advanced melanoma after PD-1 failure, following nail-biting FDA approval process.